Citadel Advisors
TPI

Citadel Advisors’s TIANYIN PHARMACEUTICAL TPI Stock Holding History

Citadel Advisors’s Portfolio TPI Stock Details TPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-108,025
Closed -$18K – 9013
2015
Q4 		$18K Buy
108,025
+86,435
+400% +$18.8K ﹤0.01% 8028
2015
Q3 		$5K Buy
21,590
+9,791
+83% +$2.97K ﹤0.01% 8653
2015
Q2 		$5K Sell
11,799
-29,389
-71% -$13.4K ﹤0.01% 8553
2015
Q1 		$19K Buy
+41,188
New +$23.4K ﹤0.01% 7965
2014
Q4 		– Sell
-14,831
Closed -$9K – 8952
2014
Q3 		$9K Sell
14,831
-3,577
-19% -$2.26K ﹤0.01% 7795
2014
Q2 		$13K Sell
18,408
-20,684
-53% -$16.4K ﹤0.01% 7507
2014
Q1 		$38K Buy
39,092
+24,289
+164% +$24.4K ﹤0.01% 6948
2013
Q4 		$12K Buy
+14,803
New +$13.6K ﹤0.01% 6678

Other funds holding TPI

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAM
Pope Asset Management Memphis, Tennessee $162M AUM
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
CHP
Cable Hill Partners Portland, Oregon $1.02B AUM 8.59% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's TPI Position: Q1 2016 in Review

Citadel Advisors sold out of TIANYIN PHARMACEUTICAL (TPI) in Q1 2016, closing a stake of 108,025 shares — an estimated $18K sold.

Citadel Advisors first reported a position in TPI in Q4 2013 and held it in 8 quarters. The position peaked at $38K in Q1 2014. 5 funds tracked by Wall St. Rank hold TPI as of Q1 2016.

  • Citadel Advisors reported no remaining TIANYIN PHARMACEUTICAL position as of Q1 2016 after selling out during the quarter.
  • Citadel Advisors sold 108,025 TIANYIN PHARMACEUTICAL shares in Q1 2016, an estimated $18K.
  • Citadel Advisors first reported a position in TIANYIN PHARMACEUTICAL in Q4 2013 and held it in 8 quarters.
  • Citadel Advisors's TIANYIN PHARMACEUTICAL position peaked at $38K in Q1 2014.
  • 5 funds tracked by Wall St. Rank held TIANYIN PHARMACEUTICAL as of Q1 2016.

Based on Citadel Advisors's 13F filing for Q1 2016, filed 13 May 2016.